# Impact of Ketoflex 12/3 Diet on Early-to-Mid Stage Alzheimer's Progression

> **NCT06898424** · NA · COMPLETED · sponsor: **Prof. Lutfu Hanoglu, MD** · enrollment: 60 (actual)

## Conditions studied

- Alzheimer Type Dementia
- Alzheimer's Disease (AD)

## Interventions

- **BEHAVIORAL:** Ketoflex 12/3 Diet

## Key facts

- **NCT ID:** NCT06898424
- **Lead sponsor:** Prof. Lutfu Hanoglu, MD
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-03-01
- **Primary completion:** 2024-09-30
- **Final completion:** 2024-10-31
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2026-03-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06898424

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06898424, "Impact of Ketoflex 12/3 Diet on Early-to-Mid Stage Alzheimer's Progression". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06898424. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*